A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours

Anne E. Cust; Amelia K Smit; Georgina Fenton; Lucinda Freeman; David Espinoza; Rachael L Morton; Phyllis Butow; Matthew H Law; Kate Dunlop; Louise A. Keogh; Michael G. Kimlin; Judy Kirk; Suzanne Dobbinson; Peter A Kanetsky; Graham J Mann; Ainsley J Newson

doi:10.1200/JCO.2016.34.15_suppl.1556

Back

A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours

Abstract

Peer reviewed

A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours

Anne E. Cust, Amelia K Smit, Georgina Fenton, Lucinda Freeman, David Espinoza, Rachael L Morton, Phyllis Butow, Matthew H Law, Kate Dunlop, Louise A. Keogh, …

Journal of Clinical Oncology, Vol.34(15 suppl), pp.1556-1556

American Society of Clinical Oncology (ASCO) Annual Meeting, 52nd (Chicago, United States, 03-Jun-2016 - 07-Jun-2016)

2016

DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.1556

Files and links (1)

url

https://doi.org/10.1200/JCO.2016.34.15_suppl.1556View

Published Version

Abstract

Background: Melanoma is highly preventable. We aimed to evaluate the feasibility and acceptability of giving information on personalised genomic risk of melanoma to the public, and its impact on behaviours, psychosocial and ethical issues. Methods: We recruited 120 people (22-69 years); consent was 41% overall but differed by age and sex. Participants were randomised to the intervention (personal genomic risk of melanoma based on variants in 21 genes, with a personalised booklet and telephone-based genetic counselling; plus educational materials) or the waitlist control (educational materials only). Follow-up was conducted after 3-months. Results: 118 (98%) completed baseline data and were randomised (intervention=60; control=58). Follow-up questionnaires were completed by 108 (92%) participants and 4-day objective UV measures by 101 (86%). Intervention participants reported high satisfaction with the risk booklet (mean 8.6, SD 1.6) and genetic counselling (mean 8.1, SD 2.2) on a 0-10 scale. Preliminary outcomes at 3-months suggest there were some beneficial changes to preventive behaviours, particularly in the high- and average-risk groups, but most were not statistically significant (Table). There were no consistent differences in psychosocial outcomes between the study groups. Conclusions: Results from this pilot study demonstrate the feasibility and acceptability of giving information on personalised genomic risk of melanoma to the public. A larger trial with longer follow-up is needed to evaluate effectiveness and cost-effectiveness. Clinical trial information: 12615000356561.

Details

Title: A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours
Authors: Anne E. Cust (Author) - Sydney School of Public Health, and Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Amelia K Smit (Author) - Sydney School of Public Health, The University of Sydney, Sydney, Australia
Georgina Fenton (Author)
Lucinda Freeman (Author)
David Espinoza (Author) - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
Rachael L Morton (Author) - NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
Phyllis Butow (Author) - Psycho-oncology Co-operative Research Group, School of Psychology, The University of Sydney, Sydney, Australia
Matthew H Law (Author) - UNSW Australia
Kate Dunlop (Author) - The Centre for Genetics Education, NSW Health, Sydney, Australia, Sydney, Australia
Louise A. Keogh (Author) - The University of Melbourne, Melbourne, Australia
Michael G. Kimlin (Author) - University of the Sunshine Coast, Queensland, School of Health and Sport Sciences - Legacy
Judy Kirk (Author) - Westmead Clinical School, and Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia
Suzanne Dobbinson (Author) - Cancer Council Victoria, Melbourne, Australia
Peter A Kanetsky (Author) - Cancer Epidemiology Program, Moffitt Cancer Center, Tampa, FL
Graham J Mann (Author) - Centre for Cancer Research, Westmead Institute for Medical Research, and Melanoma Institute Australia, University of Sydney, Sydney, Australia
Ainsley J Newson (Author) - Centre for Values, Ethics and the Law in Medicine, Sydney School of Public Health, The University of Sydney, Sydney, Australia
Publication details: Journal of Clinical Oncology, Vol.34(15 suppl), pp.1556-1556
Conference details: American Society of Clinical Oncology (ASCO) Annual Meeting, 52nd (Chicago, United States, 03-Jun-2016 - 07-Jun-2016)
Publisher: American Society of Clinical Oncology
DOI: 10.1200/JCO.2016.34.15_suppl.1556
ISSN: 1527-7755
Organisation Unit: University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy
Language: English
Record Identifier: 99656597802621
Output Type: Abstract

Metrics

20 Record Views

1 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Oncology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites